Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Just Maybe?

<< Previous

Bullboard Posts

Next >>

Post by baggerx99on May 04, 2021 7:31pm

255 Views

Post# 33129252

Just Maybe?

There are so many impatient investors in ATE that any reasonable hostile offer will be gobbled up, that could be as low as $2B, primed for this to playout. Super deal for any BP

Standing in the way and maybe intentional by mgmt.....
Delay in amalgamating Holdings into Therapeutics is to muddle/deter a BP from making a hostile takeover offer.

Dan and team expanding pipeline and extending IP protection, is this give BP a sense of incompleteness and avoidance?

Make anyone wonder if there are any partnering discussions with BP, is it just a bone Dan has been dangling to investors for years?

Same ole song and dance from Dan, time for Dan to step up and deliver......

<< Previous

Bullboard Posts

Next >>

Mullen Group: Navigates market challenges towards success